MyFinsight
Home
Blog
About
Proceeds from maturities
and sale of...
$39,522K
(-79.25%↓ Y/Y)
Net cash (used in)
provided by investing...
$14,005K
(-63.19%↓ Y/Y)
Canceled cashflow
$25,517K
Net increase in
cash, cash...
-$1,509K
(-121.65%↓ Y/Y)
Canceled cashflow
$14,005K
Stock-based compensation
expense
$3,683K
(-74.65%↓ Y/Y)
Accrued expenses
$3,324K
(240.85%↑ Y/Y)
Non-cash royalty revenue
-$1,523K
(-175.40%↓ Y/Y)
Accounts receivable
-$1,275K
(-175.58%↓ Y/Y)
Depreciation and
amortization expense
$1,185K
(-64.11%↓ Y/Y)
Non-cash interest
associated with the sale of...
$814K
(158.18%↑ Y/Y)
Operating lease,
right-of-use assets
-$584K
(83.81%↑ Y/Y)
Other long-term
assets
-$34K
Income tax receivable
-$19K
(99.94%↑ Y/Y)
Other long-term
liabilities
$8K
(-61.90%↓ Y/Y)
Amortization of premiums on
marketable securities
-$8K
(99.45%↑ Y/Y)
Proceeds from the
exercise of stock options
$492K
(423.40%↑ Y/Y)
Purchase of marketable
securities
$25,510K
(-81.91%↓ Y/Y)
Purchase of property and
equipment
$7K
(-99.94%↓ Y/Y)
Net cash used in
operating activities
-$9,972K
(21.99%↑ Y/Y)
Canceled cashflow
$12,457K
Net cash provided by
(used in) financing...
-$5,542K
(69.71%↑ Y/Y)
Canceled cashflow
$492K
Net loss
-$19,501K
(69.14%↑ Y/Y)
Accounts payable
-$1,076K
(-82.99%↓ Y/Y)
Operating lease
liabilities
-$880K
(-163.58%↓ Y/Y)
Prepaid expenses and
other current assets
$769K
(135.39%↑ Y/Y)
Premium paid on
marketable securities
$203K
Payments on royalty sale
liability, net of imputed...
$6,034K
(-66.71%↓ Y/Y)
Back
Back
Cash Flow
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)
source: myfinsight.com